BioAlliance Pharma Receives Approval to Begin ReLive Phase III Clinical Trial in Primary Liver Cancer in the US and Germany

BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology and to… Regulatory News: BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology and to supportive care products, announces that it has received authorization to start its Phase III ReLive clinical trial in primary liver cancer in the U.S. (IND approval), following the review of the Livatag® development program by the FDA, as well as in Germany after the German health agency green light. “The deployment strategy planned was to implement the clinical trial first in France, then to expand it to Europe and then to the United States in 2014. The schedule is currently fully respected as the study is already implemented